InMed Pharmaceuticals: InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"
InMed Pharmaceuticals (INM) expects to complete its merger with Mentari Therapeutics on November 6, 2026, and begin trading on Nasdaq as Mentari Therapeutics (MTRI) on November 9, 2026. The company will redomesticate from Canada to Nevada. Shareholders may receive contingent value rights, but those who buy shares on November 5, 2026, will not qualify.
How this was made
The 30-second read
Why it matters
The merger creates a new public company, changes domicile, and introduces a contingent value right structure, all of which are new market information.
Market read
First disclosure of merger closing date and new ticker provides a clear trading catalyst for INM shareholders and potential investors in the upcoming MTRI listing.
What to watch
Potential dilution from CVR issuance and redomestication costs may temper price gains.
Background
InMed Pharmaceuticals (NASDAQ: INM) is merging with Mentari Therapeutics, creating a new Nasdaq-listed entity MTRI.
Ticker impact
InMed Pharmaceuticals announced the expected closing of its merger with Mentari Therapeutics and the upcoming Nasdaq trading under the new ticker MTRI.
likely upside as the market prices in the merger completion and new Nasdaq listing.
The announcement is the first disclosure of the closing date and new ticker, creating a clear catalyst for traders.
Market effects
Biotech and pharma sector may see heightened M&A activity as the deal highlights consolidation trends.
Canadian biotech exposure shifts to US listing, modest impact on Canadian market.
Adds a new Nasdaq-listed biotech, modest global relevance.
Counterpoint
If the merger faces regulatory delays, the anticipated upside could be overstated.
Key entities
- companyInMed Pharmaceuticals
Biopharma company currently listed as INM.
- companyMentari Therapeutics
Merger partner, will become the surviving entity.
